DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01740921

GLP-1ADDS

CompletedPhase NA

GLP-1 and Microvascular Function in Type 2 Diabetes

Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

39

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7-8.5%

Primary endpoint

•Baseline skin maximum hyperaemia

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01740921
Org study ID066
Secondary ID10/H0106/29Research Ethics Committee

Timeline

Milestones

Study first posted2012-12-04estimated
Last update posted2017-02-17actual
Study start2011-01 (month precision)
Primary completion2015-12actual (month precision)
Study completion2016-02actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes and an HbA1C between 7-8.5% on a stable dose of sulphonylurea and/or metformin

Exclusion criteria

•use of insulin
•corticosteroids
•contraceptives, tamoxifen
•methotrexate
•DPP-IV inhibitors
•pregnancy
•lactation
•endocrine disorders
•acute MI or cerebrovascular disease
•Raynaud's disease or connective tissue disease
•current or previous history of malignancy
•subjects treated with ergotamine derivatives
•unstable blood pressure for the last 3 months
•current treatment with warfarin
•subjects on any anti-inflammatory or anti-platelet agents
•history of any bleeding disorders and GI bleeds.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Cardiometabolic biomarkers
2

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

change of baseline endothelial-dependent vasodilation at 4 months

Time frame:baseline and 4 months

change from baseline, improvement

Other/protocol endpoint/low confidence

change of baseline adipose tissue inflammation at 4 months

Time frame:baseline and 4 months

change from baseline, improvement

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

change of baseline skin maximum hyperaemia at 4 months

Time frame:baseline and 4 months

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

change of baseline peripheral arterial tone at 4 months

Time frame:baseline and 4 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

change of baseline capillary density at 4 months

Time frame:baseline and 4 months

change from baseline, improvement

Other/protocol endpoint/low confidence

change of baseline clot structure at 4 months

Time frame:baseline and 4 months

change from baseline, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.